RCUS Arcus Biosciences, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1724521 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-58.3%
TTM net income YoY-32.8%
TTM EPS YoY-6.4%
Revenue 3-yr CAGR-5.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-475.0%
Net margin-453.0%
FCF margin-466.0%
EBITDA margin-465.0%
Returns
ROE-114.1%
ROA-50.6%
ROIC (approx.)-124.0%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets56.2%
Debt / equity0.28x
Current ratio3.34x
Interest coverage-43.18x
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.3%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.00M | $41.00M | $17.00M | $33.00M | $26.00M | $160.00M | $28.00M | $26.00M |
| R&D expense | $117.00M | $113.00M | $122.00M | $121.00M | $141.00M | $139.00M | $122.00M | $101.00M |
| SG&A expense | $23.00M | $24.00M | $29.00M | $26.00M | $27.00M | $29.00M | $28.00M | $28.00M |
| Operating income | -$131.00M | -$96.00M | -$134.00M | -$114.00M | -$142.00M | -$8.00M | -$122.00M | -$103.00M |
| Interest expense | $3.00M | $3.00M | $3.00M | $2.00M | $3.00M | $2.00M | $1.00M | $2.00M |
| Pretax income | -$128.00M | -$91.00M | -$128.00M | -$106.00M | -$135.00M | $0 | -$112.00M | -$93.00M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.00M |
| Net income | -$128.00M | -$91.00M | -$128.00M | -$106.00M | -$135.00M | $0 | -$112.00M | -$94.00M |
| EBITDA | -$129.00M | -$93.00M | -$132.00M | -$111.00M | -$140.00M | -$6.00M | -$119.00M | -$100.00M |
| EPS (basic) | -1.00 | -0.72 | -1.02 | — | -1.27 | 0.00 | -1.14 | — |
| EPS (diluted) | -1.00 | -0.72 | -1.02 | — | -1.27 | 0.00 | -1.14 | — |
| Weighted avg. shares (diluted) | 127.40M | 126.10M | 125.40M | — | 106.50M | 106.50M | 98.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $151.00M | $150.00M | $201.00M | $222.00M | $238.00M | $248.00M | $192.00M | $150.00M |
| Short-term investments | $479.00M | $552.00M | $621.00M | $759.00M | $593.00M | $663.00M | $805.00M | $828.00M |
| Current assets | $664.00M | $756.00M | $844.00M | $1.01B | $857.00M | $946.00M | $1.03B | $1.02B |
| PP&E, net | $33.00M | $36.00M | $38.00M | $40.00M | $42.00M | $44.00M | $46.00M | $47.00M |
| Total assets | $818.00M | $924.00M | $997.00M | $1.14B | $974.00M | $1.07B | $1.16B | $1.15B |
| Current liabilities | $199.00M | $198.00M | $209.00M | $231.00M | $235.00M | $210.00M | $192.00M | $226.00M |
| Long-term debt | $102.00M | $101.00M | $100.00M | $99.00M | $98.00M | $97.00M | $48.00M | $48.00M |
| Total debt | $102.00M | $101.00M | $100.00M | $99.00M | $98.00M | $97.00M | $48.00M | $48.00M |
| Total liabilities | $460.00M | $460.00M | $473.00M | $508.00M | $538.00M | $526.00M | $625.00M | $665.00M |
| Shareholders' equity | $358.00M | $464.00M | $524.00M | $631.00M | $436.00M | $549.00M | $531.00M | $485.00M |
| Net debt | -$49.00M | -$49.00M | -$101.00M | -$123.00M | -$140.00M | -$151.00M | -$144.00M | -$102.00M |
| Shares outstanding | 127.60M | 127.00M | 125.50M | 125.30M | 107.10M | 106.40M | 105.90M | 92.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$88.00M | -$119.00M | -$138.00M | -$120.00M | -$97.00M | -$133.00M | -$132.00M | -$100.00M |
| Capital expenditure | $0 | $0 | $0 | $1.00M | $0 | $0 | $1.00M | $1.00M |
| Free cash flow | -$88.00M | -$119.00M | -$138.00M | -$121.00M | -$97.00M | -$133.00M | -$133.00M | -$101.00M |
| Investing cash flow | $82.00M | $52.00M | $114.00M | -$182.00M | $79.00M | $137.00M | $32.00M | $51.00M |
| Financing cash flow | $7.00M | $16.00M | $3.00M | $286.00M | $8.00M | $52.00M | $142.00M | -$2.00M |
| Depreciation & amortization | $2.00M | $3.00M | $2.00M | $3.00M | $2.00M | $2.00M | $3.00M | $3.00M |
| Stock-based compensation | $16.00M | $15.00M | $19.00M | $15.00M | $14.00M | $15.00M | $16.00M | $17.00M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.